Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional

Assessment Of Sildenafil On Erectile Function And Intercourse Satisfaction And To Validate A New Subject Questionnaire

ClinicalTrials.gov ID: NCT00147628

Public ClinicalTrials.gov record NCT00147628. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 9:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Double-Blind Placebo Controlled, Flexible-Dose Study With An Open-Label Phase To Assess The Efficacy Of Sildenafil Citrate On Erectile Function And Intercourse Satisfaction As Well As To Validate The Sexual Experience Questionnaire And Its Treatment Responsiveness In Men With Erectile Dysfunction

Study identification

NCT ID
NCT00147628
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Enrollment
209 participants

Conditions and interventions

Conditions

Interventions

  • sildenafil citrate Drug
  • placebo for sildenafil citrate Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2005
Primary completion
Not listed
Completion
Aug 31, 2006
Last update posted
Jan 31, 2021

2005 – 2006

United States locations

U.S. sites
20
U.S. states
13
U.S. cities
20
Facility City State ZIP Site status
Pfizer Investigational Site Huntsville Alabama
Pfizer Investigational Site San Diego California
Pfizer Investigational Site Aurora Colorado
Pfizer Investigational Site Miami Florida
Pfizer Investigational Site Ocala Florida
Pfizer Investigational Site Tallahassee Florida
Pfizer Investigational Site Jeffersonville Indiana
Pfizer Investigational Site Des Moines Iowa
Pfizer Investigational Site Shreveport Louisiana
Pfizer Investigational Site Las Vegas Nevada
Pfizer Investigational Site Garden City New York
Pfizer Investigational Site Kingston New York
Pfizer Investigational Site New York New York
Pfizer Investigational Site Poughkeepsie New York
Pfizer Investigational Site Fargo North Dakota
Pfizer Investigational Site Cincinnati Ohio
Pfizer Investigational Site Houston Texas
Pfizer Investigational Site San Antonio Texas
Pfizer Investigational Site Seattle Washington
Pfizer Investigational Site Spokane Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00147628, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 31, 2021 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00147628 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →